HBV Reactivation in Anti CD20 Treatment - Trial NCT05768061
Access comprehensive clinical trial information for NCT05768061 through Pure Global AI's free database. This phase not specified trial is sponsored by HaEmek Medical Center, Israel and is currently Not yet recruiting. The study focuses on Hepatitis B. Target enrollment is 5000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
HaEmek Medical Center, Israel
Timeline & Enrollment
N/A
Dec 16, 2021
Dec 01, 2023
Primary Outcome
HBV DNA in the blood.
Summary
The goal of this observational study is to test and describe the frequency of hepatitis B
 virus reactivation in patients who received anti-CD20 drugs for a wide variety of autoimmune
 and hemato-oncological diseases in order to find out whether a group of patients from a
 certain field was more sensitive to treatment in this respect than patients from other
 fields.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05768061
Non-Device Trial